INCY:NSD-Incyte Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 108.27

Change

-0.38 (-0.35)%

Market Cap

USD 23.62B

Volume

0.74M

Average Target Price

USD 94.83 (-12.41%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.14 (-1.05%)

USD76.11B 50.45 37.87
REGN Regeneron Pharmaceuticals, Inc

-0.54 (-0.08%)

USD65.50B 31.28 21.67
SGEN Seattle Genetics, Inc

-0.61 (-0.35%)

USD30.38B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-4.46 (-3.97%)

USD23.85B 10.60 9.11
BMRN BioMarin Pharmaceutical Inc

+0.75 (+0.59%)

USD23.14B 201.24 120.72
MRNA Moderna, Inc

+0.49 (+0.80%)

USD22.86B N/A N/A
GMAB Genmab A/S

+0.86 (+2.50%)

USD22.35B 60.04 6.37
ALNY Alnylam Pharmaceuticals, Inc

+0.42 (+0.26%)

USD18.21B N/A N/A
BNTX BioNTech SE

-1.78 (-2.57%)

USD15.72B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.51 (+3.82%)

USD15.64B N/A N/A

ETFs Containing INCY

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 5.15 % 0.35 %

+0.80 (+0.48%)

USD0.47B
BIGT:LSE L&G Pharma Breakthrough U.. 3.35 % 0.75 %

-12.00 (-1.22%)

USD0.02B
ETLI:F L&G Pharma Breakthrough U.. 3.35 % 0.75 %

-0.13 (-1.15%)

USD0.02B
ETLI:XETRA L&G Pharma Breakthrough U.. 3.35 % 0.75 %

-0.17 (-1.52%)

USD0.02B
IBB iShares Nasdaq Biotechnol.. 2.43 % 0.47 %

+0.75 (+0.54%)

USD8.84B
BTEK:LSE iShares Nasdaq US Biotech.. 2.40 % 0.35 %

-0.07 (-1.42%)

USD0.22B
BTEE:LSE iShares Nasdaq US Biotech.. 2.40 % 0.35 %

-0.09 (-1.40%)

USD0.22B
BTEC:LSE iShares Nasdaq US Biotech.. 2.09 % 0.35 %

-0.09 (-1.43%)

USD0.07B
ZBIO ProShares UltraPro Short .. 2.09 % 0.95 %

N/A

USD2.51M
BIS ProShares UltraShort Nasd.. 2.09 % 0.95 %

-0.08 (-1.04%)

USD0.01B
ZHU:CA BMO Equal Weight US Healt.. 1.93 % 0.35 %

+0.41 (+1.11%)

USD0.03B
ZUH:CA BMO Equal Weight US Healt.. 1.91 % 0.35 %

+0.12 (+0.19%)

USD0.39B
RPG Invesco S&P 500 Pure Grow.. 1.56 % 0.35 %

+1.39 (+1.05%)

USD2.30B
CURE Direxion Daily Healthcare.. 0.00 % 1.08 %

+0.15 (+0.26%)

USD0.15B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.11 (-1.88%)

N/A
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.99% 65% D 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.99% 65% D 80% B-
Trailing 12 Months  
Capital Gain 29.17% 61% D- 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.17% 61% D- 78% C+
Trailing 5 Years  
Capital Gain 0.15% 65% D 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.15% 63% D 46% F
Average Annual (5 Year Horizon)  
Capital Gain 4.74% 58% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.74% 57% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 38.36% 57% F 31% F
Risk Adjusted Return 12.36% 56% F 35% F
Market Capitalization 23.62B 99% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 47.64 18% F 22% F
Price/Book Ratio 11.94 15% F 10% F
Price / Cash Flow Ratio 33.23 3% F 9% F
EV/EBITDA 35.20 13% F 18% F
Management Effectiveness  
Return on Equity -18.69% 89% B+ 36% F
Return on Invested Capital 16.68% 92% A- 90% A-
Return on Assets -7.20% 89% B+ 29% F
Debt to Equity Ratio 0.70% 84% B 90% A-
Technical Ratios  
Short Ratio 4.74 36% F 25% F
Short Percent 4.24% 59% F 43% F
Beta 1.04 75% C 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.